脊柱关节炎中bDMARD起始与持续性的性别差异:REGISPON-3注册研究17年随访
该纵向观察研究基于西班牙REGISPONSER注册队列411例脊柱关节炎患者(男271例、女140例),比较两性起始bDMARD的时间及第一、二线治疗持续性。结果显示两性起始时间无显著差异,但男性第一线bDMARD中位持续时间为88个月、女性为48个月(Log-Rank P=0.004),第二线分别为260个月与133个月(Log-Rank P=0.0007)。
要点
- 两性bDMARD起始时间无显著差异,无论从症状起始还是从诊断时计算。
- 男性第一线bDMARD中位持续性88个月,显著长于女性的48个月(P=0.004)。
- 男性第二线bDMARD中位持续性260个月,显著长于女性的133个月(P=0.0007)。
核心结论
- 脊柱关节炎患者起始bDMARD的时机在两性间相当,但女性生物制剂治疗持续性显著短于男性。
研究设计与样本
- 纵向观察研究分析西班牙REGISPONSER注册队列411例脊柱关节炎患者(男271例、女140例),2004至2007年入组,17年后(2021至2024年)在REGISPON-3研究中复评。
- 纳入要求为风湿科医生确诊脊柱关节炎且两个时间点均有可用数据。
- 采用Kaplan-Meier生存曲线、Cox比例风险模型和负二项回归评估性别特异性治疗结局差异。
主要发现
- 两性bDMARD起始时间无显著差异,无论从症状起始还是从诊断时计算。
- 男性第一线bDMARD中位持续性为88个月,女性为48个月(Log-Rank P=0.004)。
- 男性第二线bDMARD中位持续性为260个月,女性为133个月(Log-Rank P=0.0007)。
- 多变量Cox模型识别出按性别不同的bDMARD起始预测因素。
- 女性因不良事件停药报告更频繁,但两性停药主要原因均为疗效不足。
关键数值与推荐
- 第一线bDMARD中位持续性:男性88个月 vs 女性48个月,Log-Rank P=0.004。
- 第二线bDMARD中位持续性:男性260个月 vs 女性133个月,Log-Rank P=0.0007。
临床怎么用
- 临床中应关注女性脊柱关节炎患者bDMARD持续性较短的现象,加强随访与停药原因评估。
- 女性因不良事件停药更频繁,治疗选择与监测时需考虑性别差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study examines sex differences in the initiation and retention rate of biological DMARDs among patients with spondyloarthritis (SpA) over a 17-year follow-up period and identifies sex-specific predictors of these treatment outcomes. METHODS: This longitudinal observational study analysed data from 411 patients (271 males, 140 females) enrolled between 2004 and 2007 in the Spanish REGISPONSER registry (baseline) and re-evaluated 17 years later (2021-2024) in the REGISPON-3 study. Inclusion required a rheumatologist-confirmed diagnosis of SpA and the availability of data at both time points. Baseline and follow-up data were used to compare the time to initiation of bDMARDs and treatment persistence on the first and second lines of bDMARDs between sexes. Kaplan-Meier survival curves, Cox proportional hazards models and negative binomial regressions were employed to assess sex-specific differences in treatment outcomes. RESULTS: No notable differences were found between males and females in the initiation time of bDMARDs, regardless of whether it was measured from the onset of symptoms or the time of diagnosis. However, males exhibited a longer median persistence on the first bDMARD (88 months vs 48 months, Log-Rank P =0.004) and the second bDMARD (260 months vs 133 months, Log-Rank P =0.0007) compared with females. Multivariable Cox models identified distinct predictors of bDMARD initiation, varying by sex. Adverse events were reported more frequently as reasons for discontinuation in females, although inefficacy remained the primary reason for both sexes. CONCLUSION: Although the timing for starting bDMARDs in SpA patients was comparable between sexes, women exhibited significantly shorter biological treatment persistence.
引用
- Moldovan DMM, Ladehesa-Pineda L, Puche-Larrubia MÁ, et al. Sex-based differences in bDMARD initiation and persistence in spondyloarthritis: a 17-year follow-up study from the REGISPON-3 registry. Rheumatology (Oxford). 2026. PMID: 41863321. doi:10.1093/rheumatology/keag138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。